Skip to main content
OpenTrials
Completed

NCT Number: NCT04842149

The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease

The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with small intestinal Crohn's disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gastrounit, Copenhagen University Hospital Hvidovre

Hvidovre, Copenhagen, 2650, Denmark

About this study

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with an incidence rate at 11/100 000 per year in Denmark.

The disease can potentially affect the entire gastrointestinal tract, though the most common affected area is terminal ileum and the adjacent part of colon.

CD is a result of both genetic and environmental factors together with the intestinal microbiota, however the precise etiology is unclear.

A change of the intestinal microbiota with a reduced occurrence of e.g. Bacteroides species, Firmicutes and the anti-inflammatory bacteria Faecalibacterium prausnitzii is found in CD patients compared to healthy controls. Also a reduction of the mucosa-associated Bifidobacteria has been associated with the risk of mucosal inflammation.

The hypothesis that an imbalance between potentially beneficial and pathogenic bacteria contribute to the pathogenesis of IBD, including CD, has led to the suggestion that manipulation of the microbiota may be an attractive target for therapeutic interventions in IBD.

A new probiotic bacterium, Bifidobacterium breve Bif195 (Bif195) has been identified and has shown great effects on preventing enteropathy and ulcers on the gut mucosa in healthy volunteers given acetylsalicylic acid (13), and thereby Bif195 has also shown a potential in reducing gut permeability defects. This bacterium has not yet been investigated in CD patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with small intestinal CD
  • Fecal calprotectin ≥ 250 ug/g
  • IUS evidence of small bowel inflammation with wall thickness ≥ 4 mm
  • At least 3 months af stable medical treatment
  • Able to read and speak Danish

Exclusion criteria

  • Positive rectal swab for pathogenic microorganisms
  • Use of antibiotics, probiotics and systemic glucocorticosteroids within 4 weeks prior to inclusion
  • Participation in other clinical trials within 30 days prior to inclusion
  • Pregnancy, planned pregnancy or breast feeding
  • Psychiatric disease
  • Abuse of alcohol or drugs

Treatment and study plan

Bif195 capsules

Dietary Supplement

1 capsule daily for 8 weeks

Placebo capsules

Dietary Supplement

1 capsule daily for 8 weeks

Primary outcomes

  1. Change in Bowel Wall Thickness (BWT) from baseline measured by intestinal ultrasound (IUS) at 8 weeks

    Time frame: 8 weeks

    IUS will be performed in the non-fasting patient lying in supine position with a high-end ultrasound machine (Siemens Sequoia) with 10L4 transducer.

Secondary outcomes

  1. Change in fecal calprotectin level from baseline at 8 weeks

    Time frame: 8 weeks

    measured from a fecal sample

  2. Change in severity of symptoms from baseline measured by Harvey-Bradshaw index (HBI) at 8 weeks

    Time frame: 8 weeks

    HBI is a disease activity index for Crohns disease and consists of clinical parameters

  3. Change in quality of life from baseline measured by Inflammatory Bowel Disease Questionnaire (IBDQ) Questionnaire Scores at 8 weeks

    Time frame: 8 weeks

    The IBDQ is a widely used instrument to assess QoL among IBD patients and consists of 32 questionaire

  4. The change from baseline on Color Doppler Imaging Score (0-3) including inflammatory fat and ulceration (yes/no) at 8 weeks

    Time frame: 8 weeks

    measured by intestinal ultrasound (IUS)

  5. Adverse and severe adverse events

    Time frame: 16 weeks

    Registered, if any events. Reported according to IHC-GCP

Sponsors and collaborators

Lead sponsor

Hvidovre University Hospital

Other

Collaborators

  • Novonesis

Registry information

Official study title

The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 13, 2021
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.